Rab33a Mediates Anterograde Vesicular Transport for Membrane Exocytosis and Axon Outgrowth

Hitomi Nakazawa, Tadayuki Sada, Michinori Toriyama, Kenji Tago, Tadao Sugiuira, Mitsunori Fukuda, and Naoyuki Inagaki

Axon outgrowth requires plasma membrane expansion, which results from post-Golgi vesicular transport and fusion. However, the molecular mechanisms regulating post-Golgi vesicular trafficking for membrane expansion and axon outgrowth remain unclear. Here, we show that Rab33a expression became upregulated during axon outgrowth of cultured rat hippocampal neurons. Rab33a was preferentially localized to the Golgi apparatus and to synaptophysin-positive vesicles that are transported along the growing axon. Previous studies showed that synaptophysin is localized to post-Golgi vesicles transported by fast axonal transport in developing neurons. Reduction of Rab33a expression by RNAi (RNA interference) inhibited the anterograde transport of synaptophysin-positive vesicles, leading to their decrease in axonal tips. Furthermore, this treatment reduced membrane fusion of synaptophysin-positive vesicles at the growth cones and inhibited axon outgrowth. Overexpression of Rab33a, on the other hand, induced excessive accumulation of synaptophysin-positive vesicles and concurrent formation of surplus axons. These data suggest that Rab33a participates in axon outgrowth by mediating anterograde axonal transport of synaptophysin-positive vesicles and their concomitant fusion at the growth cones.

Introduction

Throughout axon outgrowth, neurons undergo dramatic expansion of the plasma membrane. An axon of 1 μm in diameter growing at a rate of 500 μm/d must expand its surface membrane by 1500 μm²/d, while the surface membrane area of a cell body 10 μm in diameter is ~400 μm². The rough endoplasmic reticulum and Golgi apparatus in the neuronal cell body serve as the primary site for the generation of plasmalemmal precursor vesicles (Futerman and Banker, 1996; Pfenninger, 2009; Sann et al., 2009). Although less is known about the vesicular fusion events that underlie axonal membrane expansion, a number of studies suggest that growth cones are sites of exocytosis and membrane expansion for axon outgrowth (Bray, 1970; Lockerbie et al., 1991; Craig et al., 1995; Igarashi et al., 1996; Pfenninger, 2009; Eva et al., 2010; Bloom and Morgan, 2011; Wang et al., 2011).

Received Feb. 29, 2012; revised July 11, 2012; accepted July 25, 2012.

Author contributions: H.N., T. Sada, M.T., K.T., M.F., and N.I. designed research; H.N., T. Sada, and M.T. performed research; H.N., T. Sada, and T. Sugiuira analyzed data; H.N. and N.I. wrote the paper.

This research was supported in part by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) and Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI), the Global COE (Centers of Excellence) Program at Nara Institute of Science and Technology (NAIST) (MEXT), Osaka Medical Research Foundation for Incurable Diseases, and NAIST Interdisciplinary Frontier Research Project. We thank Drs. Yuichi Sakumura, Michihito Igarashi, Hiroshi Itoh, Sadayoshi Shiosaka, and Yasumasa Bessho for discussions; Dr. Ian Smith for reviewing the manuscript, and Dr. Masayoshi Matsumoto for technical advice.

The authors declare no competing financial interests.

Correspondence should be addressed to Naoyuki Inagaki, Laboratory of Neuronal Cell Morphogenesis, Graduate School of Biological Sciences, Nara Institute of Science and Technology, Ikoma, Nara 630-0192, Japan. E-mail: ninagaki@bs.naist.jp.

DOI: 10.1523/JNEUROC10989-12.2012
Copyright © 2012 the authors 0270-6474/12/3212712-14$15.00/0

Cite this article as: Nakazawa et al., Rab33a Mediates Anterograde Vesicular Transport for Membrane Exocytosis and Axon Outgrowth, The Journal of Neuroscience, 2012, 32(37), 12712–12725.
that are transported along growing axons. Synaptophysin is localized to post-Golgi vesicles transported by fast axonal transport in developing neurons (Fletcher et al., 1991; Phelan and Gordon-Weeks, 1992; Nakata et al., 1998; Rosso et al., 2004); at the growth cones, synaptophysin-positive vesicles are thought to be added to the plasma membrane for membrane expansion (Igaraishi et al., 1997). Our data suggest that Rab33a mediates the anterograde axonal transport of these post-Golgi synaptophysin-positive vesicles, thereby contributing to membrane insertion at the growth cones and to axon outgrowth.

Materials and Methods

Cultures, transfection, and drug treatment. Hippocampal neurons prepared from embryonic day 18 (E18) rat embryos were seeded on cover-slips coated with poly-D-lysine (Sigma-Aldrich) and laminin (Iwaki), and prepared from embryonic day 18 (E18) rat embryos were seeded on cover-slips coated with poly-D-lysine and laminin (Iwaki, and cultured in Neurobasal medium (Invitrogen) supplemented with B27 supplement (Invitrogen) and 1 mM glutamine without a glia feeder layer, as described previously (Mori et al., 2007). The cells were transfected with vectors using Nucleofector (Lonza) before plating. For nocodazole treatment, hippocampal neurons cultured for 48 h were incubated with 7 μM nocodazole (Sigma-Aldrich) for 2 h before fixation. cdNA constructs. Full-length cdNA of rat Rab33a was amplified by PCR from a rat brain cdNA library (Clontech Laboratories) with the primers 5'-GCATTGCAATGGCCAGGCATCCTGGGCGATG-3' and 5'-GCATTGCAATCAAAAGGACAGAATTTGTACTTGAAC-3'. Preparation of cdNA of mouse Rab33a Q5 RL (a constitutive active mutant) was reported previously (Itoh et al., 2006). cdNA of an inactive rat Rab33a mutant was produced by making a threonine-to-arginine substitution (T50R; Kobayashi et al., 2009) using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene) with the primers 5'-TCCAACCTGCTGGGAAGGC-3' and 5'-TCAGGGCGGCTTCCACGTTG-3'. Full-length cdNA of rat synaptophysin was amplified with the primers 5'-TAGGGATCCGCGGAGGCG-3' and 5'-GCGGATCCCTTGACCT-3'. The cdNA constructs were subcloned into pCMV-Tag with a β-actin promoter (provided by J. Miyazaki, Osaka University, Osaka, Japan; Niwa et al., 1991), pEGFP-C1 (Clontech Laboratories), and pmRFP (provid by Dr. R. Tsien, University of California, San Diego, La Jolla, CA) vectors.

Immunofluorescence analysis of synaptophysin-containing vesicles. Puriﬁcation of synaptophysin-containing vesicles was performed as described previously (Fukuda, 2004). Briefly, Dynabeads M-280 coated covalently with sheep anti-mouse IgG (Dynal) was incubated with anti-synaptophysin antibody (H-8; Santa Cruz Biotechnology) or control mouse IgG. Hippocampal neurons were homogenized and incubated with magnetic beads coated with primary antibody. The bound fractions were analyzed by immunoblot.

RNAi. For vector-based RNAi (RNA interference) of Rab33a, we used the BLOCK-IT Pol II miR RNAi Expression Vector kit (Invitrogen). The targeting microRNA (miRNA) sequence 5'-CAGGACAGAAGGCTTCCGTTCCGTA-3' corresponds to nucleotides 278–298 in the coding region of rat Rab33a and sequence 5'-TGGACCTGCTCCAGCAGTTA-3' corresponds to 365–383, whereas the control vector pcDNA 2.2-GW/EmGFP-miR-neg encodes a miRNA which does not target any known vertebrate gene. To ensure high-level expression of miRNA before neurite extension, hippocampal neurons prepared from E18 rat embryos and transfected with miRNA were cultured on uncoated polystyrene plates. After a 24 h incubation to induce miRNA expression, the cells were collected and cultured on coverslips coated with poly-D-lysine and laminin.

Immunocytochemistry, immunoblot, and microscopy. Immunocytochemistry and immunoblot were performed as described previously (Mori et al., 2007). For 5-chloromethylfluorescein diacetate (CMFDA) and 7-amino-4-chloromethylcoumarin (CMAC) staining, neurons were incubated with CMFDA (1:500 dilution) and CMAC (1:2000 dilution; both from Invitrogen) for 2 h before fixation. Fluorescence images of neurons were acquired using an Axioimager2 fluorescence microscope (Carl Zeiss) equipped with a Plan-Apochromat 63× oil, 1.40 NA (numerical aperture), a Plan-NeoFluar 40×, 0.75 NA and 20×, 0.50 NA objectives, an AxioCamMRm CCD camera (Carl Zeiss), and AxioVision3 imaging software (Carl Zeiss). Pseudo-color images of the ratio of Rab33a immunoreactivity to CMFDA staining and line-scan data were obtained using MetaMorph software (MDS Analytical Technologies). The relative fluorescence intensity of synaptophysin immunoreactivity and neurite length were analyzed with Multi Gauge software (Fujifilm). Time-lapse microscopy was performed at 37°C using a fluorescence microscope (IX81N-ZDC; Olympus) equipped with a CCD camera (CA4742-80-12AG; Hamamatsu). Live-cell confocal fluorescence microscopy was performed at 37°C using a fluorescence microscope (Axio Observer Z1; Carl Zeiss) equipped with an α Plan-Apochromat 100× oil, 1.46 NA objective, an LSM 710 scan module (Carl Zeiss), and imaging software (ZE-NW2009; Carl Zeiss). Total internal reflection fluorescence (TIRF) microscopy was performed at 37°C using a fluorescence microscope (ECLIPSE TE2000-U; Nikon) equipped with an Apo TIRF 60× oil, 1.49 NA objective (Nikon) and a CCD camera (C9100; Hamamatsu). The acquired images were analyzed with ImageJ (NIH).

Analysis of guanine nucleotides bound to Rab33a proteins. Guanine nucleotides bound to GTP-binding proteins were analyzed as described previously (Satoh and Kaziro, 1995). Briefly, HEK293T cells expressing Rab33a proteins were metabolically radiolabeled with [35]P, (1.2 μCi/dish) for 3 h in phosphate-free DMEM, and Rab33a proteins were immunoprecipitated with an anti-FLAG M2 monoclonal antibody. Guanine nucleotides bound to Rab33a proteins were separated by thin-layer chromatography.

Materials. Anti-Myc, tau-1, anti-synaptophysin, anti-MAP-2, anti-GFP, anti-giantin, and anti-Trk antibodies were obtained from MBL, Millipore Bioscience Research Reagents, Progen, Sigma-Aldrich, MBL, Abcam, and Santa Cruz Biotechnology, respectively. Anti-TGN38, anti-GM130, and anti-adaptn y antibodies were obtained from BD Transduction Laboratories. Anti-Rab4, Rab5, Rab8, and Rab11 antibodies were obtained from BD Transduction Laboratories. Anti-Rab7, Rab9 and Rab10 antibodies were obtained from Abcam. Rabbit polyclonal antibody against Rab33a was produced as previously reported (Tsuoib and Fukuda, 2006). Anti-actin antibody was obtained from Millipore Bioscience Research Reagents. The plasmid 24478: CMV::SynPhy H4 was purchased from Addgene.

Statistical analysis. Significance was determined by unpaired Student’s t tests in most cases. For multiple comparisons in Figure 8C, we used one-way ANOVA with Schaffer’s post hoc test. In the statistical analysis for Figure 7B, neurons with one neurite longer than 100 μm and over twice as long as any other neurite were counted as neurons with an axon (stage 3 neurons; neurons with multiple axons were excluded; Mori et al., 2007).

Results

Rab33a is upregulated during axon outgrowth and preferentially accumulates in axons

To analyze the functions of Rab33a in neurons, we first examined its tissue and intracellular distribution. Consistent with previous reports (Zheng et al., 1997; Cheng et al., 2006; Lee et al., 2006), immunoblot analysis showed that Rab33a is expressed in the rat brain (Fig. 1A). On the other hand, it was undetectable in peripheral tissues including heart, liver, spleen, kidney, lung, skeletal muscle, and placenta. Rab33a expression peaked around E18 in the developing brain, and decreased moderately after postnatal day 7 (P7; Fig. 1B). The processes of axon and dendrite formation have been extensively studied using cultured rat hippocampal neurons (Craig and Banker, 1994). They first form several immature minor processes during the first 12–24 h after plating (stage 2). After 0.5–1.5 d in vitro (DIV), one of the neurites extends rapidly to become an axon (stage 3), while the others later become dendrites (stage 4, DIV4). The level of Rab33a expression increased during the transition from stage 2 to stage 3 in these neurons, and peaked on DIV7 (Fig. 1C). Thereafter, Rab33a expression returned to a relatively low level by DIV14, when neuronal networks become established in culture (stage 5). Thus, both in the brain and in cultured hippocampal neurons, the ex-
pression of Rab33a is upregulated during the period of axon formation and outgrowth.

Immunocytochemical analysis of cultured hippocampal neurons showed a widespread distribution of endogenous Rab33a in stage 2–4 neurons (Fig. 1D–F). To examine the relative accumulation of Rab33a, we used the green volume marker CMFDA as an internal standard (Rab33a immunoreactivity/CMFDA staining; Toriyama et al., 2006). In stage 2, Rab33a immunoreactivity showed a moderate accumulation in the growth cones of minor processes (Fig. 1D, arrowheads). In stage 3, Rab33a accumulated in the growth cones of axons as well as of minor processes (Fig. 1E, arrows and arrowheads). Stage 4 neurons showed remarkably more Rab33a accumulation in axons (Fig. 1F, arrows): Rab33a immunoreactivity was detected in the cell bodies and dendrites, but the relative Rab33a accumulation in axonal growth cones and shafts was markedly higher than in these regions.

**Figure 1.** Expression and intracellular localization of Rab33a. A, Immunoblot analysis of Rab33a in adult rat tissues. B, C, Immunoblot analysis of Rab33a in developing rat brain (B) and in rat cultured hippocampal neurons at stage 2 (cultured for 22 h), stage 3 (cultured for 65 h), stage 4 (cultured for 7 d), and stage 5 (cultured for 14 d) (C). Immunoblots with anti-actin antibody served as loading controls. D–F, Immunofluorescence localization of Rab33a in stage 2 (D), stage 3 (E), and stage 4 (F) hippocampal neurons. Neurons were double-stained by anti-Rab33a antibody (red) and the volume marker CMFDA (green). Pseudo-color images show the relative concentration of Rab33a (Rab33a immunoreactivity/CMFDA staining). Quantitative profiles show the relative fluorescence intensities of Rab33a (top) and CMFDA (middle) and the relative concentration of Rab33a (bottom). Arrows and arrowheads denote axon growth cones and minor process growth cones, respectively. Insets in D–F show enlarged views of the growth cone in the rectangles. Scale bars: D, E, 20 μm; F, 50 μm.
Rab33a is localized to the Golgi apparatus and synaptophysin-positive vesicles transported along axons

We further analyzed the subcellular localization of Rab33a in hippocampal neurons. Rab33a showed punctate and widespread distribution in the cell body. A part of Rab33a-immunoreactive puncta accumulated in the intracellular region where the Golgi markers giantin (Linstedt and Hauri, 1993), GM130 (Nakamura et al., 1995), adaptin γ (Robinson, 1990), and TGN38 (Luzio et al., 1990) were localized (Fig. 2A–D, top). To confirm Golgi localization of these Rab33a, we treated the neurons with nocodazole, which induces the formation of highly polarized Golgi ministacks (Rogalski and Singer, 1984). Incubation of the neu-

Figure 2. Rab33a is localized to the Golgi apparatus. A–D Immunofluorescence localization of Rab33a and the Golgi markers giantin (A), GM130 (B), adaptin γ (C), and TGN38 (D) in the cell bodies of hippocampal neurons under control (top) or nocodazole (bottom) treatment. Arrowheads indicate colocalization of Rab33a with the Golgi markers. Scale bar, 10 μm.
rons with 7 μM nocodazole induced formation of Golgi ministacks dispersed throughout the cell bodies (Fig. 2 A–D, bottom). This treatment led to a similar dispersal of Rab33a localization throughout the cell bodies. As shown in Figure 2, the dispersed Rab33a immunoreactivity colocalized partially with each of the dispersed Golgi markers: 14 ± 2.5% of the giantin-positive area overlapped with the Rab33a-positive area; 9.0 ± 2.1% of the GM130-positive area overlapped with the Rab33a-positive area; 12 ± 2.0% of the adaptin γ-positive area overlapped with the Rab33a-positive area; and 8.9 ± 1.8% of the TGN38-positive area overlapped with the Rab33a-positive area. Together, these data suggest that a subpopulation of Rab33a in the cell body is localized to the Golgi apparatus. As Rab family proteins play a key role in membrane trafficking, we monitored the movement of EGFP-Rab33a by live cell imaging. EGFP-Rab33a-positive puncta were observed in the soma; they were mobile and likely represented intracellular vesicular transport (Fig. 3A).

EGFP-Rab33a-containing vesicles also moved dynamically in neurites, in both anterograde and retrograde directions (Fig. 3A, kymographs). As shown in Figure 3B, Rab33a partially colocalized with synaptophysin-positive vesicles in axonal shafts (25.0 ± 1.9%, n = 399 vesicles). Live imaging of hippocampal neurons expressing EGFP-Rab33a and red fluorescent protein (RFP)-synaptophysin revealed that EGFP-Rab33a was cotransported with RFP-synaptophysin along axons (Fig. 3C). To confirm that synaptophysin and Rab33a are present on the same secretory vesicles, synaptophysin-containing vesicles were affinity-purified with anti-synaptophysin-coated beads. As shown in Figure 3D, Rab33a was copurified with synaptophysin-containing vesicles. Rab33a also localized to synaptophysin-positive vesicles in axonal growth cones, but the degree of colocalization was lower than that in the axonal shafts (8.0 ± 0.5%, n = 814 vesicles; Fig. 3E, arrowheads). Synaptophysin is a vesicular transmembrane protein that is sorted at the Golgi apparatus into the exocytic...
pathway and transported by fast axonal transport to the plasma membrane at nerve terminals, where it cycles between the plasma membrane and endosomes (De Camilli and Jahn, 1990; Kelly, 1991; Régnier-Vigouroux et al., 1991; Nakata et al., 1998; Kaether et al., 2000). Before the formation of synaptic contacts, it also accumulates in distal axons and growth cones of developing neurons (Fletcher et al., 1991; Phelan and Gordon-Weeks, 1992).

To determine whether Rab33a is localized to post-Golgi synaptophysin-positive vesicles or to endocytic synaptophysin-positive vesicles, we performed double immunostaining for Rab33a and endocytic Rabs. As shown in Figure 4A, Rab33a did not colocalize with endocytic Rabs: Rab4, Rab5, and Rab10 located to early endosomes (van der Sluijs et al., 1992; Sönntichsen et al., 2000; Babbey et al., 2006; Deinhardt et al., 2006), and Rab7 and Rab9 located to late endosomes (Lombardi et al., 1993; Deinhardt et al., 2006), and Rab8 and Rab11 located to recycling endosomes (Ullrich et al., 1996; Sönntichsen et al., 2000; Hattula et al., 2006; Roland et al., 2007; Ascano et al., 2009); immunoblot data for the ant-Rab antibodies are shown in Figure 4B. This is consistent with a previous report that Rab33a localizes to secretory vesicles in PC12 cells (Tsuboi and Fukuda, 2006). Rab33a also did not localize to Trk-positive vesicles, which are reported to be transported by Rab27 and Rab11 (Arimura et al., 2009; Ascano et al., 2009). Given its accumulation in the Golgi apparatus (Fig. 2), these results suggest that Rab33a is most likely associated with the post-Golgi synaptophysin-positive vesicles that are transported along axons.

Reduction of Rab33a expression inhibits anterograde axonal transport of synaptophysin-positive vesicles

Next, we analyzed the involvement of Rab33a in axonal vesicular transport using synaptophysin as a vesicle marker: vesicles that moved along proximal regions of axons (200 μm length) adjacent to the soma were monitored (Fig. 5A). In agreement with previous reports (Nakata et al., 1998; Kaether et al., 2000), vesicles labeled by RFP-synaptophysin moved in both anterograde and retrograde directions (Fig. 5A, kymograph). They often switched their direction of movement, and some were immobile during the observation period. We categorized the patterns of their movement during 20 s observations (0.1 s interval) into three groups: (1) vesicles that showed anterograde net movement (anterograde), (2) vesicles that showed retrograde net movement (retrograde), (3) and those did not show detectable net movement (immobile).

Rab33a expression was suppressed using a vector-based RNAi system that expresses miRNA against Rab33a. A reduction of endogenous Rab33a in hippocampal neurons by two miRNAs (#1 and #2) was confirmed by immunoblot (Fig. 5B) and immunocytochemical (Fig. 5C) analyses. Knockdown of Rab33a significantly decreased the number of total (Fig. 5A) and anterograde and immobile RFP-synaptophysin-positive vesicles observed in the regions analyzed (Fig. 5E). On the other hand, the number of retrograde vesicles did not change significantly following Rab33a RNAi. Figure 5, F and G, shows further analysis of the velocity of the moving vesicles labeled by RFP-synaptophysin. In neurons expressing a control miRNA, the mean velocities of the anterograde and retrograde movement were 3.5 ± 0.4 μm/s and 2.5 ± 0.3 μm/s, respectively (Fig. 5F). Suppression of Rab33a expression by miRNAs...
Figure 5. Rab33a is involved in the anterograde axonal transport of synaptophysin-positive vesicles. A, A schematic illustration of the region of observation of mRFP-synaptophysin-positive vesicles (left) and a kymograph of the transport (right). Images were captured every 100 ms for 20 s in an axon. B, Suppression of Rab33a by miRNAi in hippocampal neurons. Proteins extracted from hippocampal neurons expressing control miRNA or miRNA against Rab33a (#1 or #2) were subjected to SDS-PAGE and the amount of Rab33a in each sample was examined by immunoblot. C, Rab33a immunoreactivity of neurons transfected with control miRNA or miRNA against Rab33a (#1 or #2). Neurons were fixed at 36 h in culture. The immunoreactivity of Rab33a in GFP-positive neurons was compared with that of control miRNA neurons. The arrowheads and arrows indicate GFP-positive transfected and untransfected neurons, respectively. D, Total vesicle number observed in the boxed region in A. Error bars indicate SEM. *p < 0.05 and **p < 0.005 relative to control, Student’s t tests. E, The number of anterograde, retrograde, and immobile vesicles observed in the region in A. Error bars indicate SEM. *p < 0.05 and **p < 0.01 relative to control, Student’s t tests. F, Mean velocities of anterograde (left) and retrograde (right) transport of mRFP-synaptophysin-positive vesicles. Error bars indicate SEM. **p < 0.005 relative to control, Student’s t tests. G, The number of vesicles with indicated velocities observed in the region in A. A total of 450 vesicles in 23 neurons for control miRNA, 318 vesicles in 27 neurons for Rab33a miRNA #1, and 321 vesicles in 22 neurons for Rab33a miRNA #2 were examined in four independent experiments. Scale bars: A, 50 μm; C, 20 μm.
or #2 remarkably decreased the mean velocity of anterograde movement. Histogram analysis of the velocity shows that fast components of the transport (15/11022 m/s) were reduced (Fig. 5G). In contrast, no significant differences were observed in the mean velocity of the retrograde transport (Fig. 5F). The reduction of both the number and the velocity of the anterogradely moving vesicles thus suggest that Rab33a is involved in anterograde transport of synaptophysin-positive vesicles.

Reduction of Rab33a expression inhibits membrane fusion of synaptophysin-positive vesicles at the growth cones

Next, we examined the possible role of Rab33a in axonal membrane insertion. Endogenous synaptophysin was preferentially localized in growing axons of control neurons, as reported previously (Fletcher et al., 1991; Phelan and Gordon-Weeks, 1992) (Fig. 6A). In agreement with the above-mentioned data demonstrating the involvement of Rab33a in anterograde transport of synaptophysin-positive vesicles, Rab33a RNAi led to a significant reduction of endogenous synaptophysin intensity in the distal regions of axons (Fig. 6A, rectangles). The total amount of synaptophysin in hippocampal neurons was not affected by Rab33a RNAi (Fig. 6B).

The reduction of synaptophysin level in distal axons by Rab33a RNAi led us to further examine the correlation between the Rab33a level and the insertion of synaptophysin-positive vesicles at the growth cones. We used synaptophysin

Figure 6. Rab33a is involved in fusion of synaptophysin-positive vesicles at the growth cone. A, Synaptophysin immunoreactivity of neurons transfected with control miRNA or miRNA against Rab33a. Insets in A show enlarged views of the growth cones in the rectangles. Relative fluorescence intensity of synaptophysin in the distal region of the axon (20 μm length, rectangles) was quantified. A total of 108 neurons for control miRNA, 104 neurons for Rab33a miRNA #1, and 89 neurons for Rab33a miRNA #2 were examined in three independent experiments. Error bars indicate SEM. *p < 0.05 and ***p < 0.005 relative to control, Student’s t tests. B, Immunoblot analyses of endogenous synaptophysin and Rab33a in cultured neurons transfected with control miRNA, miRNA against Rab33a #1, or miRNA against Rab33a #2. C–E, Hippocampal neurons were transfected with Syphyl and observed using TIRF microscopy. C, A growth cone of a hippocampal neuron expressing RFP and Syphyl (top). Representative images from a time-lapse series (bottom) display vesicle fusion events at the indicated areas 1 and 2 of the growth cone (arrowheads). D, Histogram of the duration of Syphyl signals in growth cones cotransfected with Syphyl and Rab33a miRNA #1 or control miRNA. E, Frequency of vesicle fusion in the growth cones was quantified. A total of 227 vesicles in 12 growth cones for control miRNA and 111 vesicles in 11 growth cones for Rab33a miRNA #1 were examined. Error bars indicate SEM. *p < 0.05 relative to control, Student’s t tests. Scale bars: A, 20 μm; C, 10 μm.
fused with a pH-sensitive GFP pHluorin (Miesenböck et al., 1998), named SypHy, as a marker of exocytosis of synaptophysin-positive vesicles (Granseth et al., 2006). SypHy is quenched by the acidic pH inside a vesicle, but fluorescence emission increases when the interior of the vesicle connects with the external medium upon exocytosis. Membrane fusion was observed using a TIRF microscope, which allows selective imaging of fluorescence signals located in close proximity (<200 nm) to the coverslips (Wang et al., 2011). The TIRF signals of SypHy were observed mainly in the soma and distal region of axons and the growth cones, consistent with previous observations that membrane insertions occur mainly in the cell bodies and distal axons (Dupraz et al., 2009; Wang et al., 2011).

Figure 6C shows representative fusion events in an axonal growth cone. Images were captured at 1 s intervals for 4 min. To exclude vesicles that were not inserted into the plasma membrane or that stayed near the membrane, we only counted signals that remained immobile for at least 2 s. The TIRF signals of SypHy were observed mainly in the soma and distal region of axons and the growth cones, consistent with previous observations that membrane insertions occur mainly in the cell bodies and distal axons (Dupraz et al., 2009; Wang et al., 2011).

Reduction of Rab33a expression inhibits axon formation and outgrowth

We further examined the effect of Rab33a RNAi on axon formation and outgrowth. Suppression of Rab33a expression led to significant inhibition in axon formation at 36 h in culture: compared with control neurons (37 ± 3.6%), only 18 ± 3.1% of the neurons with Rab33a miRNA #1 formed an axon (Fig. 7A, B), and similar results were obtained with Rab33a miRNA #2. Rab33a knockdown by miRNA #1 resulted in a 38.7% reduction in the length of the longest neurite (including the axon) and a 21.5% reduction in dendrite length, while knockdown by miRNA #2 resulted in a 38.6% reduction in axon length and a 17.7% reduction in dendrite length (Fig. 7C). Thus, we consider that Rab33a knockdown influences both axon and dendrite outgrowth; however, the effect on axon outgrowth was more marked. This is consistent with the preferential, but not exclusive, localization of Rab33a in axons (Fig. 1F). Suppression of Rab33a expression also led to a decrease in the total neurite length (Fig. 7D). However, total neurite number in the neurons expressing Rab33a miRNAs was similar to that of control neurons (Fig. 7E).
Overexpression of functional Rab33a induces excessive accumulation of synaptophysin-positive vesicles and formation of surplus axons

As previous studies report that, in many cases, overexpression of molecules involved in axon formation and outgrowth induces the formation of aberrant axons from minor processes (Inagaki et al., 2001; Kunda et al., 2001; Toriyama et al., 2006), we finally overexpressed a Myc-tagged constitutively active form of Rab33a, Myc-Rab33a Q95L. Remarkably, 17 ± 2.4% \( (p < 0.05, \text{ compared with Myc-GST (glutathione S-transferase) or Myc-Rab33a T50R}) \) of the neurons with overexpressed Myc-Rab33a Q95L bore multiple axons that were immunostained by the axon-specific marker tau-1 antibody but were immunonegative for the dendrite-specific marker anti-MAP-2 antibody (Fig. 8A–C). Multiple axons were also induced by overexpressed Myc-tagged wild-type (WT) Rab33a but not by the inactive mutant Myc-Rab33a T50R (Fig. 8C). An in vitro experiment showed that WT Rab33a and Rab33a Q95L bound GTP, but that Rab33a T50R did not (Fig. 8D), thereby indicating a guanine nucleotide dependency of Rab33a-induced aberrant axon formation. The sum of the length of neurites in neurons overexpressing Myc-Rab33a WT or Rab33a Q95L was similar to that in control neurons on DIV6 (Fig. 8E).
We also examined the localization of endogenous synaptophysin in neurites of hippocampal neurons which overexpressed Rab33a. As shown in Figure 9A, the multiple axons induced by Rab33a Q95L overexpression were enriched in endogenous synaptophysin. This is consistent with previous observations that aberrant axons induced by overexpression of molecules involved in axon formation were enriched for synaptophysin (Inagaki et al., 2001; Toriyama et al., 2006; Mori et al., 2007). To exclude the possibility that the increase of endogenous synaptophysin signal could be due to induced formation of multiple axons rather than vesicular transport, we also quantified the intensity of synaptophysin immunoreactivity in the distal parts of minor processes (20 μm length; Fig. 9B, rectangles). The intensity of endogenous synaptophysin in the minor processes of neurons overexpressing Rab33a (WT or Q95L) was ~1.5 times that in control neurons (Fig. 9B). The total amount of endogenous synaptophysin in hippocampal neurons was unaffected by Rab33a overexpression (Fig. 9C). Thus, the results from functional Rab33a overexpression experiments provide further evidence that Rab33a is involved in the transport of synaptophysin-positive vesicles and axon outgrowth.

Figure 9. Overexpression of Rab33a induces excessive accumulation of synaptophysin-positive vesicles. A, Hippocampal neurons overexpressing Myc-Rab33a Q95L were cultured for 6 d and then immunostained with anti-Myc (red) and anti-synaptophysin (green) antibodies. Arrowheads in the enlargements of the two boxed areas of the main image indicate axons labeled by anti-synaptophysin antibody. B, Synaptophysin immunoreactivity of short neurites (<100 μm) of cultured hippocampal neurons overexpressing Myc-GST, Myc-Rab33a WT, or Myc-Rab33a Q95L (left). Neurons were fixed on DIV3 and costained with the volume marker CMAC. Relative synaptophysin immunoreactivity in the distal region of minor processes (20 μm length, rectangles) was quantified (right graph). Arrows indicate the axons. A total of 37 neurons for GST, 70 neurons for Rab33a WT, and 66 neurons for Rab33a QL were examined in three independent experiments. Error bars indicate SEM. *p < 0.05 and ***p < 0.005 relative to GST, Student's t tests. C, Immunoblot analysis of endogenous synaptophysin in cultured neurons overexpressing Myc-GST, Myc-Rab33a Q95L, or Myc-Rab33a WT. Scale bars: A, 50 μm; B, 20 μm.
Discussion

Axon outgrowth is accompanied by plasma membrane expansion that results from membrane synthesis, vesicular transport and exocytosis (Bray, 1970; Lockerbie et al., 1991; Craig et al., 1995; Futerman and Banker, 1996; Pfenninger, 2009). We have shown that Rab33a expression became upregulated during axon outgrowth of cultured hippocampal neurons, where it localized to synaptophysin-positive vesicles that were transported along axons. The anterograde axonal transport of synaptophysin-positive vesicles was inhibited when Rab33a expression was reduced, leading to decreased numbers of vesicles in axonal tips. Repressing the Rab33a level further reduced both exocytosis of the synaptophysin-positive vesicles at the growth cones and axon outgrowth. In contrast, overexpression of Rab33a induced excessive accumulation of synaptophysin-positive vesicles, with a concurrent formation of supernumerary axons. Collectively, these results indicate a role for Rab33a in the anterograde transport of synaptophysin-positive vesicles, which is associated with their concomitant fusion at the growth cones and axon outgrowth.

Synaptophysin is a vesicular transmembrane protein transported from the Golgi apparatus through exocytic pathways to the plasma membrane at nerve terminals, where it cycles between the plasma membrane and early endosomes (De Camilli and Jahn, 1990; Kelly, 1991; Régnier-Vigouroux et al., 1991; Nakata et al., 1998) as a major component of synaptic vesicles (Jahn et al., 1985; Wiedemann and Franke, 1985). Synaptophysin-positive vesicles are also exported from the Golgi apparatus and localized to growing axons before the formation of synaptic contacts (Fletcher et al., 1991; Phelan and Gordon-Weeks, 1992; Rosso et al., 2004). At the growth cones, synaptophysin is localized to vesicles which are thought to be added to the plasma membrane (Saito et al., 1992; Igarashi et al., 1997). In this study, we directly demonstrated the insertion of synaptophysin-positive vesicles into the plasma membrane, by monitoring synaptophysin fused to a pH-sensitive GFP with TIRF microscopy. Vesicular insertion occurred mainly in the marginal region of the central domain of the growth cones, where plasmalemmal precursor-like vesicles are observed (Pfenninger and Friedman, 1993; Pfenninger, 2009). Subsets of axonal proteins are known to be transcytosed from the somatodendritic membrane through endosomes to the axonal membrane (Hémar et al., 1997; Sampo et al., 2003; Wisco et al., 2003; Leterrier et al., 2006; McDonald et al., 2007; Winckler and Yap, 2011). However, Rab33a accumulated in the Golgi apparatus in the cell bodies, and did not colocalize with endosome markers in the axonal shafts. Thus, we consider that Rab33a is involved in the axonal transport of Golgi-derived vesicles, rather than endosomes.

How does Rab33a promote vesicular fusion at the growth cones? As Rab33a contributes to the anterograde transport of synaptophysin-positive vesicles, the increased supply of these vesicles from the cell body may indirectly upregulate their fusion events at the growth cones. The low degree of colocalization between Rab33a and synaptophysin observed in the growth cones supports this notion, although we cannot rule out the possibility that Rab33a directly regulates the insertion of synaptophysin-positive vesicles at the growth cones. Previous studies suggest that SNARE proteins, the TC10-Exo70 complex, and Rab10 are involved in vesicular fusion at the growth cones (Igarashi et al., 1996; Dupraz et al., 2009; Bloom and Morgan, 2011; Wang et al., 2011). While the mechanisms by which Rab33a is involved in the axonal transport remain unclear, the GTP dependency of the Rab33a effects observed in this study implies that it acts via a GTP-dependent interaction with effector molecules. We reported previously that downregulation of Singar1 leads to the formation of multiple axons, indicating that Singar1 is involved in a process underlying the regulation of axon formation (Mori et al., 2007). More recently, we found that Singar1 preferentially binds with the GTP-bound form of Rab33a (H. Nakazawa and N. Inagaki, unpublished data), suggesting that it may function as an effector of Rab33a. Detailed analysis of the functional interaction between Rab33a and Singar1 and the identification of additional Rab33a effectors will improve our understanding of the mechanism involved in Rab33a-induced transport of synaptophysin-positive vesicles.

Different Rab proteins reportedly contribute to vesicular trafficking steps underlying neurite outgrowth. For example, Rab27 and Rab11 regulate the axonal transport of vesicles containing the neurotrophin receptor Trk and integrins, molecules that regulate neurite outgrowth (Arimura et al., 2009; Ascanio et al., 2009; Eva et al., 2010). Rab8, Rab11, and Rab5 are also implicated in the regulation of neurite extension (Huber et al., 1995; Shirane and Nakayama, 2006; Liu et al., 2007). We found that Rab33a did not colocalize with vesicles harboring these molecules, suggesting that it is involved in a distinct trafficking route. Given the diversity of vesicular compartments within axons, the details of how membrane pools are transported for axonal extension remain important issues for future investigation.

Rab33a and synaptophysin-positive vesicles accumulate in growing axons, implying their role in the establishment of neuronal polarity. Indeed, neuronal polarization was disrupted when the directional transport of synaptophysin-positive vesicles was impaired by Rab33a RNAi or Rab33a overexpression. The mechanisms by which Rab33a accumulates preferentially in growing axons remain to be analyzed. In neurons, fast anterograde transport is mediated principally by kinesin family proteins (Vallee and Bloom, 1991; Hirokawa and Takemura, 2005). As Rab33a gradually accumulates in axons after the axon is established (stage 4), kinesins which accumulate specifically in axons remain to be analyzed. In neurons, fast anterograde transport is mediated principally by kinesin family proteins (Vallee and Bloom, 1991; Hirokawa and Takemura, 2005). As Rab33a gradually accumulates in axons after the axon is established (stage 4), kinesins which accumulate specifically in axons, such as KIF5A, KIF5B, KIF5C, KIF3A/3B, KIF17, KIF13A, and KIF21A (Nakata and Hirokawa, 2003; Jacobson et al., 2006; Huang and Banker, 2011) may be involved in the axonal localization of Rab33a.

In conclusion, the present studies have revealed that Rab33a is a key component of axon vesicular transport pathways, which contribute to membrane exocytosis at the growth cones. The directional membrane supply from the cell body, together with local membrane endocytosis and recycling (Tojima et al., 2007; Winckler and Yap, 2011), force generation (Suter and Forscher, 2000; Bard et al., 2008; Shimada et al., 2008), and cytoskeletal dynamics (Arimura and Kaibuchi, 2005; Lowery and Van Vactor, 2009; Neukirchen and Bradke, 2011) at the growth cone, may coordinateably contribute to axon outgrowth.

References


